[
  {
    "ts": null,
    "headline": "Dr. Robert Lenz Joins Unlearn as Strategic Advisor",
    "summary": "SAN FRANCISCO, September 25, 2025--Unlearn, a leader in AI solutions for clinical trials, welcomed Dr. Robert Lenz as a strategic advisor to advise Unlearn as they expand partnerships.",
    "url": "https://finnhub.io/api/news?id=b195de3ef66704423d604b693e99aef7c6be1a32010109bbaa87a01827e20c7f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758805200,
      "headline": "Dr. Robert Lenz Joins Unlearn as Strategic Advisor",
      "id": 136883010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, September 25, 2025--Unlearn, a leader in AI solutions for clinical trials, welcomed Dr. Robert Lenz as a strategic advisor to advise Unlearn as they expand partnerships.",
      "url": "https://finnhub.io/api/news?id=b195de3ef66704423d604b693e99aef7c6be1a32010109bbaa87a01827e20c7f"
    }
  },
  {
    "ts": null,
    "headline": "Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors",
    "summary": "See why Teva Pharmaceutical Industries Limited is shifting the CNS market with Austedo sales growth, new clinical data, and falling debt. Click for my TEVA update.",
    "url": "https://finnhub.io/api/news?id=5654cabe84142939f60002314d296e69ec9908de40922b5433a5fc21b4e997df",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758800565,
      "headline": "Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors",
      "id": 136882693,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2196049070/image_2196049070.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "See why Teva Pharmaceutical Industries Limited is shifting the CNS market with Austedo sales growth, new clinical data, and falling debt. Click for my TEVA update.",
      "url": "https://finnhub.io/api/news?id=5654cabe84142939f60002314d296e69ec9908de40922b5433a5fc21b4e997df"
    }
  },
  {
    "ts": null,
    "headline": "QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published",
    "summary": "AbbVie (NYSE: ABBV) announced today that the RAMQ has listed QULIPTA® in their formulary for the prevention of chronic migraine and episodic migraine.i This will be followed by reimbursement by private plans, mimicking the public formulary. The Institut national d'excellence en santé et en services sociaux (INESSS) previously published a positive recommendation for the public listing of QULIPTA® (atogepant) in the treatment of chronic migraine in adults on July 2, 2025.ii",
    "url": "https://finnhub.io/api/news?id=204f9ca74fb1f9e8e1b7299677573d91dfe1d742a1c23063c10b25d8aff1f674",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758798060,
      "headline": "QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published",
      "id": 136883011,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) announced today that the RAMQ has listed QULIPTA® in their formulary for the prevention of chronic migraine and episodic migraine.i This will be followed by reimbursement by private plans, mimicking the public formulary. The Institut national d'excellence en santé et en services sociaux (INESSS) previously published a positive recommendation for the public listing of QULIPTA® (atogepant) in the treatment of chronic migraine in adults on July 2, 2025.ii",
      "url": "https://finnhub.io/api/news?id=204f9ca74fb1f9e8e1b7299677573d91dfe1d742a1c23063c10b25d8aff1f674"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Buy and Hold Forever",
    "summary": "These blue chip dividend stocks offer both income and growth potential.",
    "url": "https://finnhub.io/api/news?id=92adb6e93c80f3bdace8afb2d07c4139681eaea7e57b99c28ec9a7327cbf34c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758790800,
      "headline": "3 Top Dividend Stocks to Buy and Hold Forever",
      "id": 136883013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These blue chip dividend stocks offer both income and growth potential.",
      "url": "https://finnhub.io/api/news?id=92adb6e93c80f3bdace8afb2d07c4139681eaea7e57b99c28ec9a7327cbf34c7"
    }
  },
  {
    "ts": null,
    "headline": "Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC), taking place in Dubai from Wednesday 1 – Friday 3 October 2025.",
    "url": "https://finnhub.io/api/news?id=76fdb46c350999cd1165639060468b8fae2e561134f208b8e2f5c8e17ec3062f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758790800,
      "headline": "Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai",
      "id": 136883012,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC), taking place in Dubai from Wednesday 1 – Friday 3 October 2025.",
      "url": "https://finnhub.io/api/news?id=76fdb46c350999cd1165639060468b8fae2e561134f208b8e2f5c8e17ec3062f"
    }
  },
  {
    "ts": null,
    "headline": "Where Will AbbVie Be in 5 Years?",
    "summary": "This big pharmaceutical company should be significantly bigger five years from now.",
    "url": "https://finnhub.io/api/news?id=c2c67eb0e4bf3ac0f7b780ceb0eb0b7697fdc8bf99583de4a0c9225a8f638271",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758789840,
      "headline": "Where Will AbbVie Be in 5 Years?",
      "id": 136883014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "This big pharmaceutical company should be significantly bigger five years from now.",
      "url": "https://finnhub.io/api/news?id=c2c67eb0e4bf3ac0f7b780ceb0eb0b7697fdc8bf99583de4a0c9225a8f638271"
    }
  }
]